Puma Biotechnology (PBYI) Net Income towards Common Stockholders (2017 - 2025)
Historic Net Income towards Common Stockholders for Puma Biotechnology (PBYI) over the last 9 years, with Q3 2025 value amounting to $8.8 million.
- Puma Biotechnology's Net Income towards Common Stockholders fell 5647.0% to $8.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $29.9 million, marking a year-over-year increase of 2866.49%. This contributed to the annual value of $23.2 million for FY2024, which is 746.61% up from last year.
- Per Puma Biotechnology's latest filing, its Net Income towards Common Stockholders stood at $8.8 million for Q3 2025, which was down 5647.0% from $5.9 million recorded in Q2 2025.
- Over the past 5 years, Puma Biotechnology's Net Income towards Common Stockholders peaked at $20.3 million during Q3 2024, and registered a low of -$44.7 million during Q3 2021.
- Over the past 5 years, Puma Biotechnology's median Net Income towards Common Stockholders value was $3.0 million (recorded in 2025), while the average stood at $1.8 million.
- Its Net Income towards Common Stockholders has fluctuated over the past 5 years, first surged by 171000.0% in 2023, then tumbled by 44368.31% in 2024.
- Over the past 5 years, Puma Biotechnology's Net Income towards Common Stockholders (Quarter) stood at $4.2 million in 2021, then crashed by 232.72% to -$5.6 million in 2022, then skyrocketed by 318.84% to $12.3 million in 2023, then decreased by 0.31% to $12.2 million in 2024, then fell by 27.69% to $8.8 million in 2025.
- Its Net Income towards Common Stockholders was $8.8 million in Q3 2025, compared to $5.9 million in Q2 2025 and $3.0 million in Q1 2025.